ReviewAging medicine (Milton (N.S.W))2026
The Role of Artificial Intelligence in Medication Management for Older Adults: A Systematic Review.
Review in Aging medicine (Milton (N.S.W)), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Older adults face increased risks of medication non-adherence, adverse drug events, and polypharmacy due to chronic health conditions and complex drug regimens. Traditional medication management approaches often fall short in addressing these challenges. Artificial intelligence (AI) has emerged as a promising tool for enhancing medication safety and personalization in geriatric care. This systematic review aimed to explore the role of AI in medication management for older adults, highlighting its effectiveness, usability, ethical implications, and integration within healthcare systems. Following PRISMA guidelines, a comprehensive search was conducted across six databases (PubMed, Scopus, Web of Science, CINAHL, IEEE Xplore, and Cochrane Library) for studies published between January 2015 and March 2025. Eligible studies included qualitative, quantitative, and mixed-methods research on AI-based medication interventions for individuals aged 60 and above. Data were synthesized thematically. Twenty-nine studies were included. Five major themes emerged: (1) AI's ability to enhance adherence through smart reminders and automation; (2) personalized and predictive capabilities in managing complex regimens; (3) design and usability challenges among older adults; (4) ethical concerns related to trust, privacy, and autonomy; and (5) the importance of seamless integration within clinical workflows. Cross-cutting observations emphasized the need for hybrid care models, inclusive design, and digital literacy training. AI has the potential to transform geriatric medication management. However, its success depends on ethical implementation, user-centered design, healthcare integration, and attention to equity. Long-term evaluations are essential to ensure sustainable and inclusive outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.